150 related articles for article (PubMed ID: 16619515)
1. Antitumor properties and toxicity of dextran-methotrexate conjugates are dependent on the molecular weight of the carrier.
Nevozhay D; Budzynska R; Kanska U; Jagiello M; Omar MS; Boratynski J; Opolski A
Anticancer Res; 2006; 26(2A):1135-43. PubMed ID: 16619515
[TBL] [Abstract][Full Text] [Related]
2. The effect of the substitution level of some dextran-methotrexate conjugates on their antitumor activity in experimental cancer models.
Nevozhay D; Budzynska R; Jagiello M; Kanska U; Omar MS; Opolski A; Wietrzyk J; Boratynski J
Anticancer Res; 2006; 26(3A):2179-86. PubMed ID: 16827162
[TBL] [Abstract][Full Text] [Related]
3. Polyethylene glycol conjugates of methotrexate varying in their molecular weight from MW 750 to MW 40000: synthesis, characterization, and structure-activity relationships in vitro and in vivo.
Riebeseel K; Biedermann E; Löser R; Breiter N; Hanselmann R; Mülhaupt R; Unger C; Kratz F
Bioconjug Chem; 2002; 13(4):773-85. PubMed ID: 12121133
[TBL] [Abstract][Full Text] [Related]
4. The antileukemic activity of modified fibrinogen-methotrexate conjugate.
Goszczyński T; Nevozhay D; Wietrzyk J; Omar MS; Boratyński J
Biochim Biophys Acta; 2013 Mar; 1830(3):2526-30. PubMed ID: 23168301
[TBL] [Abstract][Full Text] [Related]
5. Antileukemic activity of glycated fibrinogen-methotrexate conjugates.
Kanska U; Omar MS; Budzynska R; Nevozhay D; Jagiello M; Opolski A; Boratynski J
Anticancer Res; 2005; 25(3B):2229-34. PubMed ID: 16158968
[TBL] [Abstract][Full Text] [Related]
6. Cytotoxic and antitumor effect of fibrinogen-methotrexate conjugate.
Boratyński J; Opolski A; Wietrzyk J; Górski A; Radzikowski C
Cancer Lett; 2000 Feb; 148(2):189-95. PubMed ID: 10695996
[TBL] [Abstract][Full Text] [Related]
7. Growth inhibition, drug load, and degradation studies of gelatin/methotrexate conjugates.
Ofner CM; Pica K; Bowman BJ; Chen CS
Int J Pharm; 2006 Feb; 308(1-2):90-9. PubMed ID: 16361072
[TBL] [Abstract][Full Text] [Related]
8. Induction of Au-methotrexate conjugates by sugar molecules: production, assembly mechanism, and bioassay studies.
Wang WY; Zhao XF; Ju XH; Liu P; Li J; Tang YW; Li SP; Li XD; Song FG
Int J Pharm; 2018 Mar; 538(1-2):65-78. PubMed ID: 29341908
[TBL] [Abstract][Full Text] [Related]
9. Antitumor efficacy of a novel polymer-peptide-drug conjugate in human tumor xenograft models.
Chau Y; Padera RF; Dang NM; Langer R
Int J Cancer; 2006 Mar; 118(6):1519-26. PubMed ID: 16187287
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of mannan-methotrexate conjugate in vitro and in vivo.
Budzynska R; Nevozhay D; Kanska U; Jagiello M; Opolski A; Wietrzyk J; Boratynski J
Oncol Res; 2007; 16(9):415-21. PubMed ID: 18074676
[TBL] [Abstract][Full Text] [Related]
11. The effect of molecular weight, drug load, and charge of gelatin-MTX conjugates on growth inhibition of HL-60 leukemia cells.
Chen CS; Ofner CM
Pharm Res; 2009 Feb; 26(2):338-45. PubMed ID: 18975058
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and in vitro testing of methotrexate carrier conjugates linked via oligopeptide spacers.
Fitzpatrick JJ; Garnett MC
Anticancer Drug Des; 1995 Jan; 10(1):1-9. PubMed ID: 7695810
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxicity, uptake, polyglutamate formation, and antileukemic effects of 8-deaza analogues of methotrexate and aminopterin in mice.
Kuehl M; Brixner DI; Broom AD; Avery TL; Blakley RL
Cancer Res; 1988 Mar; 48(6):1481-8. PubMed ID: 2449950
[TBL] [Abstract][Full Text] [Related]
14. The loading rate determines tumor targeting properties of methotrexate-albumin conjugates in rats.
Stehle G; Sinn H; Wunder A; Schrenk HH; Schütt S; Maier-Borst W; Heene DL
Anticancer Drugs; 1997 Aug; 8(7):677-85. PubMed ID: 9311444
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and properties of a biodegradable polymer-drug conjugate: Methotrexate-poly(glycerol adipate).
Suksiriworapong J; Taresco V; Ivanov DP; Styliari ID; Sakchaisri K; Junyaprasert VB; Garnett MC
Colloids Surf B Biointerfaces; 2018 Jul; 167():115-125. PubMed ID: 29631222
[TBL] [Abstract][Full Text] [Related]
16. Methotrexate conjugated to gold nanoparticles inhibits tumor growth in a syngeneic lung tumor model.
Chen YH; Tsai CY; Huang PY; Chang MY; Cheng PC; Chou CH; Chen DH; Wang CR; Shiau AL; Wu CL
Mol Pharm; 2007; 4(5):713-22. PubMed ID: 17708653
[TBL] [Abstract][Full Text] [Related]
17. TSPO Ligand-Methotrexate Prodrug Conjugates: Design, Synthesis, and Biological Evaluation.
Laquintana V; Denora N; Cutrignelli A; Perrone M; Iacobazzi RM; Annese C; Lopalco A; Lopedota AA; Franco M
Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27322261
[TBL] [Abstract][Full Text] [Related]
18. Influence of carrier on biodistribution and in vitro cytotoxicity of methotrexate-branched polypeptide conjugates.
Hudecz F; Clegg JA; Kajtár J; Embleton MJ; Pimm MV; Szekerke M; Baldwin RW
Bioconjug Chem; 1993; 4(1):25-33. PubMed ID: 8431509
[TBL] [Abstract][Full Text] [Related]
19. Carrier effects on antitumor activity and neurotoxicity of AZ10992, a paclitaxel-carboxymethyl dextran conjugate, in a mouse model.
Sugahara S; Kajiki M; Kuriyama H; Kobayashi TR
Biol Pharm Bull; 2008 Feb; 31(2):223-30. PubMed ID: 18239277
[TBL] [Abstract][Full Text] [Related]
20. Covalent coupling of methotrexate to dextran enhances the penetration of cytotoxicity into a tissue-like matrix.
Dang W; Colvin OM; Brem H; Saltzman WM
Cancer Res; 1994 Apr; 54(7):1729-35. PubMed ID: 7511049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
